Applied Therapeutics Inc (APLT)
1.1500  +0.0100 (0.88%)

Applied Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for patients with serious and chronic diseases, particularly those with unmet medical needs. The company's research emphasizes the discovery and advancement of therapeutics that target underlying disease mechanisms, with a primary focus on conditions such as diabetic complications and other metabolic disorders. Applied Therapeutics aims to leverage its expertise in chemistry and biology to bring effective solutions to the market, enhancing patient outcomes and addressing critical health challenges. Through its dedication to scientific rigor and the development of novel compounds, the company strives to make a meaningful impact in the field of medicine.

SummaryNewsPress ReleasesChartHistorical
Previous Close1.140
Open1.110
Bid1.120
Ask1.130
Day's Range1.081 - 1.170
52 Week Range1.081 - 10.62
Volume7,204,621
Market Cap132.07M
PE Ratio (TTM)-0.7143
EPS (TTM)-1.6
Dividend & YieldN/A (N/A)
1 Month Average Volume10,204,024

News & Press Releases

Applied Therapeutics, Inc. (APLT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws.
Via ACCESSWIRE · December 13, 2024
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Applied Therapeutics, Inc. (APLT)
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws.
Via ACCESSWIRE · December 12, 2024
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay & Murray LLP · Via Business Wire · December 12, 2024
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · December 12, 2024
(APLT) - Analyzing Applied Therapeutics's Short Interestbenzinga.com
Via Benzinga · December 6, 2024
Applied Therapeutics, Inc. Being Investigated on Behalf of Applied Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws.
Via ACCESSWIRE · December 12, 2024
The Law Offices of Frank R. Cruz Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · December 11, 2024
APLT ALERT: Kaplan Fox & Kilsheimer LLP Is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 9, 2024
APLT ALERT: Kaplan Fox & Kilsheimer LLP Is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 09, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
Via TheNewswire.com · December 9, 2024
APPLIED THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 7, 2024
APPLIED THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 07, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
Via TheNewswire.com · December 7, 2024
APPLIED THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 6, 2024
APPLIED THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
NEW YORK - (NewMediaWire) - December 06, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
Via TheNewswire.com · December 6, 2024
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Applied Therapeutics, Inc. (APLT)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 5, 2024
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Applied Therapeutics, Inc. (APLT)
NEW YORK - (NewMediaWire) - December 05, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
Via TheNewswire.com · December 5, 2024
Kaplan Fox & Kilsheimer LLP is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 4, 2024
Kaplan Fox & Kilsheimer LLP is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
Via TheNewswire.com · December 4, 2024
Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga.com
Via Benzinga · December 2, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 29, 2024
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · November 29, 2024
Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Applicationbenzinga.com
FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for resubmission or appeal.
Via Benzinga · November 29, 2024
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
By Applied Therapeutics · Via GlobeNewswire · November 27, 2024
Applied Therapeutics Reports Third Quarter 2024 Financial Results
- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025
By Applied Therapeutics · Via GlobeNewswire · November 7, 2024
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.
By Applied Therapeutics · Via GlobeNewswire · November 5, 2024
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 19, 2024